EMBC Stock Analysis: Buy, Sell, or Hold?
EMBC - Embecta Corp. Common Stock
$8.79
-0.05 (-0.57%)
▼
5d:
-2.33%
30d:
-9.47%
90d:
-27.17%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 08, 2026
Get Alerted When EMBC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EMBC appears deeply undervalued. Market expects -6.7% annual earnings decline despite 83% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: EMBC appears deeply undervalued. Market expects -6.7% annual earnings decline despite 83% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.78
Based on 3.2% avg growth
INTRINSIC VALUE TODAY
$7.93
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EMBC is currently trading at $8.79, which is considered slightly low relative to its 30-day fair value range of $8.70 to $9.88. From a valuation perspective, the stock is trading at a discount (Forward PE: 3.0) compared to its historical average (3.8). Remarkably, the market is currently pricing in an annual earnings decline of 6.7% over the next few years. This pessimistic expectation contrasts with the company's recent 82.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, EMBC is in a strong downtrend. Immediate support is located at $8.47, while resistance sits at $9.46.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.67 (+89.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EMBC is in a strong downtrend. Immediate support is located at $8.47, while resistance sits at $9.46.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.67 (+89.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$8.70 -
$9.88
Company Quality Score
59/100
(HOLD)
Options IV Signal
30th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 30th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 89.6% below Wall St target ($16.67)
Fair Price Analysis
30-Day Fair Range
$8.70 -
$9.88
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.69
(7.9%)
Support & Resistance Levels
Support Level
$8.47
Resistance Level
$9.47
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.05
Wall Street Target
$16.67
(+89.6%)
Revenue Growth (YoY)
-0.3%
Earnings Growth (YoY)
82.7%
Profit Margin
12.9%
Valuation Discount vs History
-6.7% cheaper
PE vs Historical
3.1 vs 3.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.7%
(market-implied from PE analysis)
1-Year Target
$8.20
(-7%)
2-Year Target
$7.65
(-13%)
3-Year Target
$7.14
(-19%)
3-Yr Target (if PE normalizes)
(PE: 3→4)
$8.89
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 2.3%)
$68.93
(+684%)
Base:
(SPY PE: 3.1, Growth: 2.3%)
$9.41
(+7%)
Bear:
(PE: 2.6, Growth: 2.3%)
$8.00
(-9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (4x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 3.77 | Current EPS (TTM): $2.36
Bull Case
$11.93
(+32%)
Analyst growth 22.0%, PE expands to 4.1
Base Case
$10.85
(+20%)
Market implied 22.0%, PE stable at 3.8
Bear Case
$6.05
(-33%)
Severe decline -20.0%, PE contracts to 3.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 3.1 to 3.8
Stabilization Target:
$10.94
(+24.5%)
PE Expansion Potential:
+24.5%
Share & Embed Analysis
Last updated: April 02, 2026 4:18 AM ET
Data refreshes hourly during market hours. Next update: 5:18 AM
Data refreshes hourly during market hours. Next update: 5:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EMBC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$607 | 61 BUY |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$94 | 59 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$186 | 58 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$297 | 61 BUY |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$318 | 62 BUY |
